Teva is desperate to fix its overreliance on one product—Copaxone—for about 50% of its profits. (This is a separate issue from generic competition for Copaxone.)
ABBV had a similar problem with Humira, but that’s well on its way to being rectified by growth in V-Pak and Imbruvica.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.